Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations

Radiother Oncol. 1999 Feb;50(2):167-71. doi: 10.1016/s0167-8140(98)00123-6.

Abstract

Background and purpose: Carbogen (95%O2, 5%CO2) is being used in clinical trials as a hypoxic radiosensitiser. Tolerance to carbogen can be a problem, this study compares tumour oxygenation during inhalation of hyperoxic gas containing either 2% or 5% CO2.

Materials and methods: Tumour pO2 was measured in 16 patients using the Eppendorf pO2 histograph.

Results: After breathing gas containing either 5% or 2% CO2 an increase in median pO2 was measured in every tumour, the frequency of low pO2 values ( < or = 10 mmHg) fell from 47% to 29% in the 5% group and from 55% to 17% in the 2% group.

Conclusions: This study confirms that breathing 2% CO2 and 98% O2 is well tolerated and effective in increasing tumour oxygenation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Carbon Dioxide / administration & dosage*
  • Female
  • Humans
  • Male
  • Neoplasms / metabolism*
  • Neoplasms / radiotherapy
  • Oxygen / administration & dosage*
  • Oxygen / metabolism*
  • Radiation-Sensitizing Agents / administration & dosage*
  • Treatment Outcome

Substances

  • Radiation-Sensitizing Agents
  • Carbon Dioxide
  • carbogen
  • Oxygen